In advanced MPM, the combination of durvalumab with chemotherapy resulted in an objective tumor response rate of 48%, with a median overall survival of 18.4 months, higher than historical control with chemotherapy alone, irrespective of program death-ligand 1 (PD-L1) expression (4). This evidence concerns the gene CD274 and neoplasm.